16 November 2015
EMA/CHMP/754777/2015
Procedure Management and Committees Support Division

# Committee for medicinal products for human use (CHMP)

## Draft agenda for the meeting on 16-19 November 2015

Chair: Tomas Salmonson – Vice-Chair: Pierre Demolis

16 November 2015, 13:00 – 19:30, room 2A

17 November 2015, 08:30 – 19:30, room 2A

18 November 2015, 08:30 – 19:30, room 2A

19 November 2015, 08:30 – 15:00, room 2A

**Health and safety information**

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

**Disclaimers**

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

**Note on access to documents**

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
**Telephone** +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
**Send a question via our website** www.ema.europa.eu/contact

# Table of contents

# 1. Introduction

## 1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 16-19 November 2015. See November 2015 CHMP minutes (to be published post December 2015 CHMP meeting).

## 1.2. Adoption of agenda

CHMP agenda for 16-19 November 2015

## 1.3. Adoption of the minutes

CHMP minutes for 19-22 October 2015.

# 2. Oral Explanations

## 2.1. Pre-authorisation procedure oral explanations

### 2.1.1. - mercaptamine - Orphan - EMEA/H/C/003769

Orphan Europe S.A.R.L.; treatment of cystinosis

Scope: Oral explanation

**Action**: Oral explanation to be held on Wednesday 18 November 2015 at 14:15.

List of Outstanding Issues adopted on 25.06.2015. List of Questions adopted on 22.01.2015.

### 2.1.2. - mercaptamine - Orphan - EMEA/H/C/004038

Lucane Pharma; treatment of corneal cystine deposits

Scope: Oral explanation

**Action**: Oral explanation to be held on Wednesday 18 November 2015 at 09:00.

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 26.03.2015.

### 2.1.3. - ferric maltol - EMEA/H/C/002733

treatment of iron deficiency anaemia

Scope: Oral explanation

**Action**: Oral explanation to be held on Tuesday 17 November 2015 at 09:00.

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 23.04.2015.

### 2.1.4. - dexamethasone acetate - Orphan - EMEA/H/C/004071

Laboratoires CTRS; treatment of symptomatic multiple myeloma in combination with other medicinal products.

Scope: Oral explanation

**Action**: Possible oral explanation to be held on Wednesday 18 November 2015 at 11:00.

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 18.12.2014.

### 2.1.5. - necitumumab - EMEA/H/C/003886

treatment of squamous non-small cell lung cancer

Scope: Oral explanation

**Action**: Possible oral explanation to be held on Tuesday 17 November 2015 at 11:00.

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 23.04.2015.

## 2.2. Re-examination procedure oral explanations

## 2.3. Post-authorisation procedure oral explanations

## 2.4. Referral procedure oral explanations

# 3. Initial applications

## 3.1. Initial applications; Opinions

### 3.1.1. - etanercept - EMEA/H/C/004007

treatment of arthritis

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 23.04.2015.

### 3.1.2. - brivaracetam - EMEA/H/C/003898

treatment of partial-onset seizures

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 23.04.2015.

### 3.1.3. - betulae cortex dry extract (5-10 : 1); extraction solvent: n-heptane 95% (w/w) - EMEA/H/C/003938

treatment of partial thickness wounds

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 26.02.2015.

### 3.1.4. - eptifibatide - EMEA/H/C/004104

prevention of early myocardial infarction

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 23.04.2015.

### 3.1.5. - lopinavir / ritonavir - EMEA/H/C/004025

treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children above the age of 2 years.

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 22.10.2015. List of Questions adopted on 21.05.2015.

### 3.1.6. - pegaspargase - EMEA/H/C/003789

indicated as combination therapy in acute lymphoblastic leukaemia (ALL)

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 23.07.2015. List of Questions adopted on 20.11.2014.

### 3.1.7. - opicapone - EMEA/H/C/002790

Parkinson's disease and motor fluctuations

Scope: Opinion, Similarity assessment report

**Action**: For adoption

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 23.04.2015.

### 3.1.8. - pemetrexed - EMEA/H/C/004072

unresectable malignant pleural mesothelioma
metastatic non-small cell lung cancer

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 26.03.2015.

### 3.1.9. - pemetrexed - EMEA/H/C/004109

Treatment of malignant pleural mesothelioma and non-small cell lung cancer.

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 22.10.2015, 24.09.2015. List of Questions adopted on 25.06.2015.

### 3.1.10. - recombinant l-asparaginase - Orphan - EMEA/H/C/002661

medac Gesellschaft fuer klinische Spezialpraeparate mbH; combination therapy for B/T cell lymphoblastic leukaemia (ALL) or B/T cell lymphoblastic lymphoma (LBL)

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 24.09.2015, 21.05.2015. List of Questions adopted on 25.04.2014.

### 3.1.11. - insulin human - EMEA/H/C/003858

treatment of diabetes

Scope: Opinion

**Action**: For adoption

Oral explanation was held on 20 October 2015. List of Outstanding Issues adopted on 25.06.2015. List of Questions adopted on 23.10.2014.

### 3.1.12. - pitolisant - Orphan - EMEA/H/C/002616

BIOPROJET PHARMA; treatment of narcolepsy

Scope: Opinion

**Action**: For adoption

List of Outstanding Issues adopted on 22.10.2015, 21.05.2015. List of Questions adopted on 25.09.2014.

## 3.2. Initial applications; Day 180 list of outstanding issues

### 3.2.1. - amlodipine / valsartan - EMEA/H/C/004037

treatment of essential hypertension

Scope: Day 180 list of outstanding issue

**Action**: For adoption

List of Questions adopted on 25.06.2015.

### 3.2.2. - albutrepenonacog alfa - Orphan - EMEA/H/C/003955

CSL Behring GmbH; prophylaxis and treatment of bleeding in all patients with haemophilia B, treatment of bleeding in all patients with haemophilia B

Scope: Day 180 list of outstanding issue

**Action**: For adoption

List of Questions adopted on 23.07.2015.

## 3.3. Initial applications; Day 120 list of questions

### 3.3.1. - cediranib - Orphan - EMEA/H/C/004003

AstraZeneca AB; treatment of platinum sensitive relapsed (PSR) ovarian cancer relapsed (PSR) ovarian cancer

Scope: Day 120 list of questions

**Action**: For adoption

### 3.3.2. - factor x - Orphan - EMEA/H/C/003855

BIO PRODUCTS LABORATORY; treatment of factor X deficiency

Scope: Day 120 list of questions

**Action**: For adoption

### 3.3.3. - elotuzumab - Orphan - EMEA/H/C/003967

Bristol-Myers Squibb; treatment of myeloma

Scope: Day 120 list of questions

**Action**: For adoption

### 3.3.4. - emtricitabine / tenofovir disoproxil - EMEA/H/C/004050

treatment of HIV

Scope: Day 120 list of questions

**Action**: For adoption

### 3.3.5. - grazoprevir / elbasvir - EMEA/H/C/004126

treatment of chronic hepatitis C (CHC) in adults

Scope: Day 120 list of questions

**Action**: For adoption

### 3.3.6. - reslizumab - EMEA/H/C/003912

treatment of asthma and elevated blood eosinophils who are inadequately controlled on inhaled corticosteroids

Scope: Day 120 list of questions

**Action**: For adoption

## 3.4. Update on on-going initial applications for Centralised procedure

### 3.4.1. - ixazomib - Orphan - EMEA/H/C/003844

Takeda Pharma A/S; multiple myeloma

Scope: Assessment of similarity

**Action**: For adoption

### 3.4.2. - eluxadoline - EMEA/H/C/004098

for the treatment of irritable bowel syndrome with diarrhoea

Scope: Letter from the applicant dated November 2015 requesting extension of timeframe to respond to Day 120 list of questions adopted on 24.09.2015.

**Action**: For adoption

## 3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

## 3.6. Initial applications in the decision-making phase

## 3.7. Withdrawals of initial marketing authorisation application

# 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

## 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

### 4.1.1. Pyramax - pyronaridine / pyronaridine phosphate / artesunate - EMEA/H/W/002319/X/0008/G

Shin Poong Pharmaceutical Co., Ltd.

Rapporteur: Joseph Emmerich, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Arnaud Batz

Scope: "Line Extension to add a new paediatric formulation PYRAMAX 60 mg/20 mg Granules for Oral Suspension.
The PI for Pyramax 180 mg/60 mg Film Coated Tablets has also been updated with data submitted for the line extension."

**Action**: For adoption

List of Outstanding Issues adopted on 24.09.2015. List of Questions adopted on 26.02.2015.

## 4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

### 4.2.1. Brilique - ticagrelor - EMEA/H/C/001241/X/0029/G

AstraZeneca AB

Rapporteur: Pieter de Graeff, Co-Rapporteur: Arantxa Sancho-Lopez, PRAC Rapporteur: Menno van der Elst

Scope: "Annex I_2.(c) - extension application for a new strength of 60mg with a new

indication: History of Myocardial Infarction.
C.I.4. Type II - To update the product information of the existing Brilique 90mg license with important clinical information from the PEGASUS study."

**Action**: For adoption

List of Questions adopted on 23.07.2015.

### 4.2.2. Exjade - deferasirox - Orphan - EMEA/H/C/000670/X/0043

Novartis Europharm Ltd

Rapporteur: Pierre Demolis, PRAC Rapporteur: Corinne Fechant

Scope: "Extension application for a new pharmaceutical form and new strengths (Exjade 90, 180 and 360 mg film-coated tablets)."

**Action**: For adoption

List of Questions adopted on 23.07.2015.

### 4.2.3. REVOLADE - eltrombopag / eltrombopag olamine - EMEA/H/C/001110/X/0022/G

Novartis Europharm Ltd

Rapporteur: Arantxa Sancho-Lopez, Co-Rapporteur: Greg Markey, PRAC Rapporteur: Dolores Montero Corominas

Scope: "Extension of indication for paediatric (age 1 year and above) chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who had an insufficient response to other treatments (e.g. corticosteroids, immunoglobulins).
Grouping with the line extension for one new tablet strength (12.5mg) and a new Powder for Oral Suspension formulation (25mg).
The Type II variation and the Extension are grouped within this Application. This grouping is justified, as one of the variations in the group is an extension of the marketing authorisation (Annex III of Commission Regulation (EC) No 1234/2008 of November 2008)."

**Action**: For adoption

List of Questions adopted on 25.06.2015.

## 4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

### 4.3.1. Zebinix - eslicarbazepine acetate - EMEA/H/C/000988/X/0050/G

Bial - Portela & Cª, S.A.

Rapporteur: Martina Weise, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Martin Huber

Scope: "Grouping of a line extension application to add a new pharmaceutical form (50 mg/ml oral suspension) and a type II variation (C.I.6.a New indication (paediatric indication)) to add treatment of children aged 2 years and older. Consequently, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC have been updated and the Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make minor

editorial changes in the SmPC and Package Leaflet.
The application included a revised RMP version 14.0."

**Action**: For adoption

## 4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

## 4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

# 5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

## 5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

### 5.1.1. Afinitor - everolimus - EMEA/H/C/001038/II/0048

Novartis Europharm Ltd

Rapporteur: Harald Enzmann, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber

Scope: "Extension of Indication to include a new indication for the treatment of unresectable or metastatic, well-differentiated non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease for Afinitor.
As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Furthermore, the PI is brought in line with the latest QRD template version 9.1."

**Action**: For adoption

### 5.1.2. Caprelsa - vandetanib - EMEA/H/C/002315/II/0016

AstraZeneca AB

Rapporteur: Pierre Demolis

Scope: "Extension of Indication to include paediatric indication population for Caprelsa.
As a consequence, sections 4.1, 4.2, 4.6, 4.8, 5.1 and 5.2 of the SmPC are updated in update the safety information. The Package Leaflet is updated in accordance."

**Action**: For adoption

### 5.1.3. Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0067

GlaxoSmithKline Biologicals

Rapporteur: Daniel Brasseur, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Extension of Indication to include prevention against premalignant anal lesions and anal cancer as of 9 years of age for Cervarix.
As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.
In addition, the Marketing authorisation holder (MAH) took the opportunity to update the RMP (v.11.0) including the new indication."

**Action**: For adoption

Request for Supplementary Information adopted on 25.06.2015.

### 5.1.4. Cimzia - certolizumab pegol - EMEA/H/C/001037/II/0045

UCB Pharma SA

Rapporteur: Kristina Dunder, Co-Rapporteur: Agnes Gyurasics

Scope: "Extension of indication to include treatment of severe, active and progressive rheumatoid arthritis in adults not treated previously with MTX or other disease-modifying antirheumatic drugs (DMARDs).
As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are revised in order to update the efficacy and safety information."

**Action**: For adoption

Request for Supplementary Information adopted on 21.05.2015.

### 5.1.5. Halaven - eribulin - EMEA/H/C/002084/II/0028

Eisai Europe Ltd.

Rapporteur: Filip Josephson, Co-Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of Indication to include a new indication for Halaven 0.44 mg/ml solution for injection to expand its use to the treatment of soft tissue sarcoma, following the outcome of a Phase 3 study, Study 309.
As a consequence, sections 4.1, 4.4, 4.8, and 5.1 of the SmPC are updated in order to update the safety information. The Package Leaflet and RMP are updated in accordance.
In addition, the Marketing authorisation holder (MAH) took the opportunity to update the PI in line with the latest QRD template version 9.1."

**Action**: For adoption

Similarity assessment report

### 5.1.6. Pyramax - pyronaridine / pyronaridine phosphate / artesunate - EMEA/H/W/002319/II/0002

Shin Poong Pharmaceutical Co., Ltd.

Rapporteur: Joseph Emmerich, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Arnaud Batz

Scope: "To amend SmPC section 4.1 (Therapeutic Indications) to remove restrictions on repeated course of treatment in any individual and use only in areas of low transmission with evidence ofartesmisinin resistance, based on further clinical experience. Consequent changes in SmPC sections 4.2 (Posology), 4.4 (Special warnings and precautions), 4.8 (Undesirable effects) and the PL are also included. A recommended change is made to SmPC Section 4.2 (Posology) in relation to dosing in mild to moderate renal impairment. A minor editorial adjustment is proposed to SmPC section 5.1 (Pharmacodynamic properties)."

**Action**: For adoption

Request for Supplementary Information adopted on 24.09.2015, 23.04.2015, 18.12.2014, 26.06.2014.

### 5.1.7. Revestive - teduglutide - Orphan - EMEA/H/C/002345/II/0020

NPS Pharma Holdings Limited

Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Torbjorn Callreus

Scope: "Extension of Indication to include paediatric population for Revestive.
As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated in order to update the safety information. The Package Leaflet is updated in accordance."

**Action**: For adoption

### 5.1.8. Tysabri - natalizumab - EMEA/H/C/000603/II/0077

Biogen Idec Ltd

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of Indication to include new indication for Tysabri.
As a consequence, sections 4.1 AND 4.4 of the SmPC are updated in order to provide physicians with more options for treating RRMS patients with high disease activity who fail an initial disease modifying therapy (DMT). Consequential changes to sections 4.2, 4.3, 5.1 and Package Leaflet in Sections 2 and 3 are also proposed."

**Action**: For adoption

Request for Supplementary Information adopted on 25.06.2015.

### 5.1.9. Zutectra - human hepatitis b immunoglobulin - EMEA/H/C/001089/II/0024

Biotest Pharma GmbH

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Robert James Hemmings, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: “Extension of Indication to Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative patients at least one week – instead of the approved at least 6 months - after liver transplantation for hepatitis B induced liver failure. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly.
An updated RMP has been provided.”

**Action**: For adoption

Request for Supplementary Information adopted on 22.10.2015, 23.07.2015.

### 5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

### 5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

## 6. Ancillary medicinal substances in medical devices

### 6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

### 6.2. Update of Ancillary medicinal substances in medical devices

## 7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

### 7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

## 8. Pre-submission issues

### 8.1. Pre-submission issue

#### 8.1.1. - lenvatinib - H0004224

treatment for advanced and/or metastatic RCC following disease progression after failure of treatment with 1 prior VEGF-targeted therapy

Scope: Request for an accelerated assessment

**Action:** For adoption

Letter from the company dated 14 October 2015 requesting an accelerated assessment

Rapporteur's briefing note

# 9. Post-authorisation issues

## 9.1. Post-authorisation issues

### 9.1.1. Xarelto - Rivaroxaban - EMEA/H/C/000944

Bayer Pharma AG, prevention of venous thromboembolism (VTE), prevention of venous thromboembolism (VTE), prevention of stroke and systemic embolism

Rapporteur: Kristina Dunder, Co-Rapporteur: Martina Weise,

**Scope:** Update on Rocket Trial.

**Action:** For discussion

### 9.1.2. Enbrel - etanercept - EMEA/H/C/000262/II/0184

Pfizer Limited, Rapporteur: Robert James Hemmings, PRAC Rapporteur: Rafe Suvarna,

Scope: Opinion or Request for Supplementary Information

"Update of section 4.6 of the SmPC in order to update the information on the effects of etanercept on pregnancy and lactation. The Package Leaflet and the RMP are updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the RMP in reference to past approved variations."

**Action:** For adoption

Request for Supplementary Information adopted on 24.09.2015, 25.06.2015.

### 9.1.3. Simponi - golimumab - EMEA/H/C/000992/II/0063

Janssen Biologics B.V.,

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga,

Scope: Opinion or Request for Supplementary Information

"Update of the SmPC sections 4.2 and 5.1 in order to reflect the data from a multicentre, placebo-controlled, double-blind, randomised-withdrawal, parallel group study (GO KIDS) in children (2 to 17 years of age) with active polyarticular juvenile idiopathic arthritis (pJIA). The Package leaflet is proposed to be updated accordingly. This procedure includes also an update to the RMP."

**Action:** For adoption

Request for Supplementary Information adopted on 26.03.2015.

### 9.1.4. Pheburane - sodium phenylbutyrate - EMEA/H/C/002500/II/0007

Lucane Pharma, (treatment of chronic management of urea cycle disorders

Rapporteur: David Lyons,

Scope: Opinion or Request for Supplementary information

"Update of sections 4.2 and 6.6 of the SmPC in order to providing information on the administration of the product by nasogastric tube. The Package Leaflet is updated accordingly."

**Action:** For adoption

Request for Supplementary Information adopted on 30.07.2015, 28.05.2015.

### 9.1.5. Voncento - human coagulation factor viii / human von willebrand factor - EMEA/H/C/002493/II/0017/G

CSL Behring GmbH,

Rapporteur: Pieter de Graeff, PRAC Rapporteur: Sabine Straus,

Scope: Opinion or Request for Supplementary information

"C.I.4 (type II): Update of section 4.8 of the SmPC in order to update the frequencies of undesirable effects to reflect the final clinical study data from study CSLCT-BIO-08-53 in haemophilia A paediatric patients. The Package Leaflet is updated accordingly. The submission of the final CSR CSLCT-BIO-08-53 also leads to changes to the RMP (ver. 6.1) in order update the Company Core Safety Information (CCSI).

C.I.11.z (type IB): Submission of a revised RMP in order to remove the commitment to conduct a post-marketing study for haemophilia A patients (CSLCT-BIO-12-78) for Voncento as consequence of new data from study CSLCT-BIO-08-53.

In addition, the Marketing authorisation holder (MAH) took the opportunity to combine different strengths in the SmPC and Package Leaflet."

**Action:** For adoption

## 10. Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

### 10.1.1. CERVARIX -Human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) – EMEA/H/A20/1421/C/0721/0071 GARDASIL , SILGARD - Human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) – EMEA/H/A20/1421/C/0703/0060 / EMEA/H/A20/1421/C/0732/0054 GARDASIL 9 (Human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMEA/H/A20/1421/C/3852/0001

MAHs: GlaxoSmithKline Biologicals S.A. (Cervarix), Sanofi Pasteur MSD SNC (Gardasil,

Gardasil 9), Merck Sharp & Dohme Limited (Silgard)

Rapporteurs for the Article 20 referral: PRAC Rapporteur: Julie Williams, PRAC Co-rapporteurs: Qun-Ying Yue and Jean-Michel Dogne

Individual product Rapporteurs: Rapporteur: Daniel Brasseur, Co-Rapporteur: Jan Mueller-Berghaus (Cervarix), Rapporteur: Kristina Dunder, Co-Rapporteur: Pierre Demolis (Gardasil / Silgard), Rapporteur: Kristina Dunder, Co-Rapporteur: Jan Mueller-Berghaus (Gardasil 9),

Scope: Review of the HPV vaccines to further clarify aspects of their safety profile following notification by the European Commission of a referral under Article 20 of Regulation (EC) No 726/2004, based on pharmacovigilance data.

Procedure started at PRAC in July 2015. The PRAC recommendation was adopted by PRAC during their November 2015 Plenary

**Action:** For adoption

### 10.1.2. TYSABRI - Natalizumab - EMEA/H/A-20/1416

Biogen Idec Ltd, treatment of multiple sclerosis

Rapporteur: Jan Mueller-Berghaus, Co-rapporteur: Daniela Melchiorri, PRAC Rapporteur: Brigitte Keller-Stanislawski;
Scope: Report from Scientific Advisory Group meeting held on 06.11.2015

Review of the benefit-risk balance following notification by the European Commission of a referral under Article 20(8) of Regulation (EC) No 726/2004, based on pharmacovigilance data

**Action:** For discussion

## 10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

## 10.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

## 10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

## 10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

### 10.5.1. Clenil and associated names - Beclometasone dipropionate - EMEA/H/A-30/1418

Chiesi group of companies and associated companiesScope: Opinion or List of outstanding issues

Harmonisation exercise for Clenil and associated names (beclometasone dipropionate). The review was triggered by Italy due to the need to harmonise the product information across all Member States, including the therapeutic indication, the target populations and the posology recommendations.

**Action:** For adoption

List of Questions adopted on 25.06.2015.

### 10.5.2. Cymevene IV and associated names - ganciclovir - EMEA/H/A-30/1406

F. Hoffmann-La Roche
Rapporteur: Rugile Pilviene, Co-Rapporteur: Alar Irs,

Scope: Opinion

Harmonisation exercise for Cymevene IV and associated names. The review was triggered by the European Commission in September 2014, due to the need of harmonisation of the Summary of Product Characteristics across Member State.

**Action:** For adoption

List of Outstanding Issues adopted on 23.07.2015 and 26.02.2015. List of Questions adopted on 25.09.2014.

### 10.5.3. Novantrone and associated names - mitoxantrone - EMEA/H/A-30/1399

MEDA group of companies and associated companies

Rapporteur: Pieter de Graeff, Co-Rapporteur: Robert Hemmings,

Scope: Opinion or List of outstanding issues, report from Scientific Advisory Group meeting held on 06.11.2015

Harmonisation exercise for Novantrone and associated names. The review was triggered by the European Commission, due to the need of harmonisation of the Summary of Product Characteristics across Member States.

**Action:** For adoption

List of Outstanding Issues adopted on 26.03.2015.

### 10.5.4. Lovenox and associated names – enoxaparin - EMEA/H/A-30/1429

MAH Sanofi Aventis group of companies and associated companies

Rapporteur: to be appointed, Co-Rapporteur: to be appointed,

Scope: List of questions and timetable, appointment of (Co)Rapporteur

Harmonisation exercise for Lovenox and associated names. The review was triggered by France, due to the need of harmonisation of the Summary of Product Characteristics across Member States.

**Action:** For adoption

Letter from the ANSM National Agency for Medicines and Health Products Safety (ANSM) in France dated 12 November 2015 notifying of an official referral under Article 30.

### 10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

### 10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

### 10.8. Procedure under Article 107(2) of Directive 2001/83/EC

### 10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003

### 10.10. Procedure under Article 29 Regulation (EC) 1901/2006

### 10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

## 11. Pharmacovigilance issue

### 11.1. Early Notification System

November 2015 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety Concerns) Accompanied by communication to the General Summary of recommendations and advice of PRAC meeting held on 03-06 November 2015.

**Action**: For information

## 12. Inspections

### 12.1. GMP inspections

Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections

### 12.2. GCP inspections

Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections

### 12.3. Pharmacovigilance inspections

Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

### 12.4. GLP inspections

Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections

## 13. Innovation Task Force

### 13.1. Minutes of Innovation Task Force

**Action**: For information

### 13.2. Innovation Task Force briefing meetings

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information

ITF Briefing Meeting

**Action:** For adoption

### 13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

### 13.4. Nanomedicines activities

## 14. Organisational, regulatory and methodological matters

### 14.1. Mandate and organisation of the CHMP

#### 14.1.1. Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004

Scope: CHMP guideline on conditional marketing authorisation

**Action:** For adoption for circulation to the European Commission as per Article 11 of Regulation (EC) No 507/2006

Overview of comments received on the CHMP guideline concerning conditional marketing authorisation

### 14.1.2. Information on data gathering

**Action:** For discussion

### 14.1.3. Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS)

**Action:** For adoption

### 14.1.4. Survey on the experience with Early Background Summaries

**Action:** For discussion

### 14.1.5. Follow-up from the CHMP Strategic Review & Learning Meeting in Luxembourg: action items and members' feedback

**Action:** For discussion

### 14.1.6. Revision of the Guideline on the scientific application and the practical arrangements necessary to implement the procedure for accelerated assessment pursuant to article 14(9) of regulation (EC) No 726/2004 – Rev 1

Scope: Comments received during public consultation

**Action:** For discussion

### 14.1.7. Update on call for nomination for the 5th CHMP co-opted member

Nominations for a co-opted member with expertise in Statistics and methodology, Epidemiology, Geriatrics and/or Pharmacology should be submitted by 27 November 2015.

The election of co-opted member is planned for the December 2015 CHMP Plenary.

**Action:** For discussion

## 14.2. Coordination with EMA Scientific Committees

### 14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 03-06 November 2015

**Action:** For information

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for November 2015

**Action:** For adoption

### 14.2.2. Committee for Advanced Therapies (CAT)

CAT draft minutes of meeting held on 12-13 November 2015
**Action**: For information

### 14.2.3. Committee for Herbal Medicinal Products (HMPC )

Not applicable this month

### 14.2.4. Paediatric Committee (PDCO)

PIPs reaching D30 at November 2015 PDCO

**Action:** For information

Report from the PDCO meeting held on 11-13 November 2015

**Action:** For information

### 14.2.5. Committee for Orphan Medicinal Products (COMP)

Report from the COMP meeting held on 10-12 November 2015
**Action:** For information

### 14.2.6. CMDh

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 16-18 November 2015

**Action:** For information

Letter from CMDh dated 4 November 2015 to CHMP / PKWP requesting advice on exenatide prolonged-release suspension for injection

**Action:** For discussion

Response from PKWP and RIWP on CMDh question on everolimus regarding classification of everolimus in transplant setting as narrow therapeutic index drug

CHMP sponsor: Dr Romaldas Maciulaitis

**Action:** For adoption

## 14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

### 14.3.1. Scientific Advice Working Party (SAWP)

Report from the SAWP meeting held on 3-6 November 2015. Table of conclusions

**Action:** For information

Scientific advice letters: Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

**Action:** For adoption

**Election of SAWP Member**

Scope: Election of a new SAWP member with expertise haematology, oncology, infectious diseases

**Action:** For adoption

### 14.3.2. Proposal for establishment of the Respiratory drafting group

Scope: Call for nomination of Respiratory drafting group Chairman

**Action:** For discussion

### 14.3.3. Call for nomination for Vice-chair of CVSWP - Cardiovascular Working Party

Please send your nomination for Vice-chair

**Action:** For information

### 14.3.4. Call for nomination for Vice-chair of ONCWP – Oncology Working Party

Please send your nomination for Vice-chair

**Action:** For information

### 14.3.5. Call for nomination for Vice-chair of RIWP - Rheumatology/Immunology Working Party

Please send your nomination for Vice-chair

**Action:** For information

### 14.3.6. Excipients Drafting Group (ExcpDG)

New mandate of the Excipient drafting group

**Action:** for information

## 14.4. Cooperation within the EU regulatory network

## 14.5. Cooperation with International Regulators

## 14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

## 14.7. CHMP work plan

### 14.7.1. CHMP 2016 work plan

**Action:** For discussion

## 14.8. Planning and reporting

## 14.9. Others

# 15. Any other business

## 15.1. AOB topic

## 16. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

**Oral explanations** *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

**Initial applications** *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:




The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

**Extension of marketing authorisations according to Annex I of Reg. 1234/2008** *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

**Type II variations - Extension of indication procedures** *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

**Ancillary medicinal substances in medical devices** *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

**Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004** *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

**Re-examination procedures** *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

**Withdrawal of application** *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

**Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use)** *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

**Pre-submission issues** *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

**Post-authorisation issues** *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

**Referral procedures** *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

**Pharmacovigilance issues** *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

**Inspections Issues** *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

**Innovation task force** *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

**Scientific advice working party (SAWP)** *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

**Satellite groups / other committees** *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

**Invented name issues** *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/